Clinical Trial Corticoids For Empyema And Pleural Effusion In Children (CORTEEC)
Primary Purpose
Parapneumonic Pleural Effusion, Empyema
Status
Completed
Phase
Phase 2
Locations
Spain
Study Type
Interventional
Intervention
Dexamethasone
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Parapneumonic Pleural Effusion focused on measuring pleural effusion, empyema, corticoids, dexamethasone
Eligibility Criteria
Inclusion Criteria:
- Patients between 1 and 14 year old.
- Presence of pneumonia diagnosed by clinical and radiographic criteria: cough, fever and radiological consolidation.
- Evidence of pleural effusion.
Exclusion Criteria:
- Allergy to any of the drugs included in the study.
- Immunodeficiency.
Sites / Locations
- Hospital Carlos Haya
- Complejo Hospitalario Toledo
- Hospital Principe de Asturias
- Hospital Universitario de Getafe
- Hospital Infanta Sofia
- Hospital Infantil La Paz
- Hospital Ramón y Cajal
- Hospital Universitario Gregorio Marañón
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Dexamethasone
Placebo
Arm Description
Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days. Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present Ranitidine 5 mg/kg IV, q.d. for 2 days Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.
Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days. Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present. Ranitidine 5 mg/kg IV, q.d. for 2 days. Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.
Outcomes
Primary Outcome Measures
time to resolution
days from diagnosis until criteria for cure
Secondary Outcome Measures
number of children with complications.
number of children with complications.
Number of children with complications attributable to corticoids
Hyperglycemia Signs of gastrointestinal bleeding Need of transfusion Oropharyngeal Candidiasis Allergic reaction
Full Information
NCT ID
NCT01261546
First Posted
December 15, 2010
Last Updated
May 29, 2015
Sponsor
Hospital Infanta Sofia
Collaborators
Pediatrics Spanish Association (Madrid and Castilla-La Mancha Pediatric Association), Spanish Ministry of Health.
1. Study Identification
Unique Protocol Identification Number
NCT01261546
Brief Title
Clinical Trial Corticoids For Empyema And Pleural Effusion In Children
Acronym
CORTEEC
Official Title
MULTICENTRIC, PHASE II, CLINICAL TRIAL CORTICOIDS FOR EMPYEMA AND PLEURAL EFFUSION IN CHILDREN
Study Type
Interventional
2. Study Status
Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
May 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital Infanta Sofia
Collaborators
Pediatrics Spanish Association (Madrid and Castilla-La Mancha Pediatric Association), Spanish Ministry of Health.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
STUDY JUSTIFICATION
Scientific evidence of the usefulness of corticosteroid use for infectious diseases: Corticosteroids along with antibiotic use improve survival in some infectious processes provide long term benefits and improve symptoms in many others.
Clinical Observation: the investigators observed that patients with parapneumonic pleural effusion and associated bronchospasm who were treated with corticosteroids for their bronchospasm, evolved to healing before patients who were not treated with corticosteroids (average admission days 10 vs. 17).
Rationale: the anti-inflammatory effect has been the rationale for the use of dexamethasone as an inhibitor of the inflammatory response observed after the first dose of parenteral antibiotic in bacterial meningitis. A similar effect is likely to occur in pneumonia with pleural effusion. It can be therefore hypothesized that Dexamethasone could inhibit an excessive inflammatory response by mesothelial and inflammatory cells during the early phases of parapneumonic empyema, reducing its severity and hence its complications.
OBJECTIVES
Principal: to investigate if dexamethasone 0,25mg/kg q.i.d. added to standard antibiotic therapy reduces time to resolution of parapneumonic pleural effusion.
Secondary:
2.1. Evaluate the effect of dexamethasone 0,25mg/kg q.i.d. added to standard antibiotic therapy on the development of complications during pleural effusion episode.
2.2. Evaluate the incidence of severe and non severe adverse events associated with the new treatment versus standard therapy.
METHODS
Study design: exploratory (pilot), randomized, double blinded, placebo controlled, parallel stratified design, multicentric.
Participating Hospitals (n=56, 7 patients per center):
Hospital Infanta Sofía (S. Sebastián de los Reyes, Madrid).
Hospital Universitario de Getafe
Hospital Universitario Ramón y Cajal, Madrid.
Hospital Universitario Materno-Infantil Carlos Haya, Málaga.
Hospital Infantil La Paz, Madrid.
Hospital U. Gregorio Marañón
Hospital U. Príncipe de Asturias
Hospital Virgen de la Salud, Toledo
Endpoints:
3.1. Primary: time to resolution. 3.2. Secondary endpoints:
Effectiveness: number of children with complications.
Safety (expected number: none). i) Hyperglycemia ii) Signs of gastrointestinal bleeding iii) Need of transfusion iv) Oropharyngeal Candidiasis v) Allergic reaction vi) Other adverse reactions described in the Medication Guide.
Treatment arms:
3.1. Control (0)
Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.
Cefotaxime 150 mg/kg, IV, q.d. until discharge criteria are present.
Ranitidine 5 mg/kg IV, q.d. for 2 days.
Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.
3.2. Study treatment: (1)
dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.
Cefotaxime 150 mg/kg, IV, q.d. until discharge criteria are present
Ranitidine 5 mg/kg IV, q.d. for 2 days
Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.
4. INCLUSION CRITERIA
Patients between 1 and 14 year old.
Presence of pneumonia diagnosed by clinical and radiographic criteria: cough, fever and radiological consolidation.
Evidence of pleural effusion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parapneumonic Pleural Effusion, Empyema
Keywords
pleural effusion, empyema, corticoids, dexamethasone
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dexamethasone
Arm Type
Experimental
Arm Description
Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present
Ranitidine 5 mg/kg IV, q.d. for 2 days
Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.
Ranitidine 5 mg/kg IV, q.d. for 2 days.
Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Description
Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present
Ranitidine 5 mg/kg IV, q.d. for 2 days
Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.
Ranitidine 5 mg/kg IV, q.d. for 2 days.
Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.
Primary Outcome Measure Information:
Title
time to resolution
Description
days from diagnosis until criteria for cure
Time Frame
1 month after admission
Secondary Outcome Measure Information:
Title
number of children with complications.
Description
number of children with complications.
Time Frame
3 months after diagnosis
Title
Number of children with complications attributable to corticoids
Description
Hyperglycemia Signs of gastrointestinal bleeding Need of transfusion Oropharyngeal Candidiasis Allergic reaction
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients between 1 and 14 year old.
Presence of pneumonia diagnosed by clinical and radiographic criteria: cough, fever and radiological consolidation.
Evidence of pleural effusion.
Exclusion Criteria:
Allergy to any of the drugs included in the study.
Immunodeficiency.
Facility Information:
Facility Name
Hospital Carlos Haya
City
Malaga
State/Province
Andalucia
Country
Spain
Facility Name
Complejo Hospitalario Toledo
City
Toledo
State/Province
Castilla La Mancha
Country
Spain
Facility Name
Hospital Principe de Asturias
City
Alcalá de Henares
State/Province
Madrid
Country
Spain
Facility Name
Hospital Universitario de Getafe
City
Getafe
State/Province
Madrid
Country
Spain
Facility Name
Hospital Infanta Sofia
City
San Sebastián de los Reyes
State/Province
Madrid
ZIP/Postal Code
28014
Country
Spain
Facility Name
Hospital Infantil La Paz
City
Madrid
ZIP/Postal Code
28037
Country
Spain
Facility Name
Hospital Ramón y Cajal
City
Madrid
Country
Spain
Facility Name
Hospital Universitario Gregorio Marañón
City
Madrid
Country
Spain
12. IPD Sharing Statement
Citations:
PubMed Identifier
28363363
Citation
Tagarro A, Otheo E, Baquero-Artigao F, Navarro ML, Velasco R, Ruiz M, Penin M, Moreno D, Rojo P, Madero R; CORTEEC Study Group. Dexamethasone for Parapneumonic Pleural Effusion: A Randomized, Double-Blind, Clinical Trial. J Pediatr. 2017 Jun;185:117-123.e6. doi: 10.1016/j.jpeds.2017.02.043. Epub 2017 Mar 28.
Results Reference
derived
Learn more about this trial
Clinical Trial Corticoids For Empyema And Pleural Effusion In Children
We'll reach out to this number within 24 hrs